Protagonist Therapeutics increases inducement plan share reserve by 500,000 shares

Protagonist Therapeutics, Inc

Compensation Committee approved amendment to 2018 Inducement Plan on Feb 15, 2022, adding 500,000 shares (total 1,750,000).
New shares reserved exclusively for inducement grants to new employees not previously employed by the company.
Amendment adopted without stockholder approval under Nasdaq Rule 5635(c)(4) for inducement awards.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.